Medicus Pharma (NASDAQ:MDCX) (TSXV:MDCX) announced a collaborative agreement with Swanielle to explore the expansion of its SKNJCT-003 Phase 2 clinical study for the treatment of basal cell carcinoma in the Asia-Pacific region.
Under the agreement, Swanielle will assist Medicus in identifying pharmaceutical or biotech companies as potential partners to expand its Phase 2 study, which is currently underway at nine clinical sites in the U.S. and has already randomized more than 25% of the 60 patients expected to enroll. The company plans to initiate an interim data analysis in Q1 2025 and submit its findings to the FDA as a part of a package seeking a Type C meeting in Q2 2025.
“We are delighted with the progress we have made in advancing the clinical development program of our novel, non-invasive treatment to cure the most common cancer in the world,” said Dr. Raza Bokhari, Executive Chairman and CEO.
“The collaboration with Swanielle to explore expansion of our clinical study to treat BCC in Southeast Asia will help us gather useful efficacy and safety data which will strengthen the analysis of the pivotal trial that we plan to commence in not-so-distant future,” Dr. Bokhari added.
